Subscribe to RSS
DOI: 10.1055/s-2006-951606
Serum Markers of Hepatocellular Carcinoma
Publication History
Publication Date:
18 October 2006 (online)
![](https://www.thieme-connect.de/media/sld/200604/lookinside/thumbnails/10.1055-s-2006-951606-1.jpg)
ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in some areas of the world with increasing incidence worldwide. Most of patients with HCC are diagnosed at a late stage. Therefore, the prognosis of HCC patients is generally very poor with a 5-year survival rate of less than 5%. Screening strategies including α-fetoprotein (AFP) and ultrasound every 6 months in patients with liver cirrhosis, the major risk factor for HCC development, have been recommended to detect HCC at earlier stages amenable to effective treatment strategies. AFP, however, is a marker with poor sensitivity and specificity and the ultrasound is highly dependent on the operator's experience. Apart from AFP, lens culinaris agglutinin-reactive AFP and des-gamma carboxyprothrombin and several other biomarkers (e.g., glypican-3, human hepatocyte growth factor, and insulin-like growth factor) have been proposed as markers for HCC detection. In addition, with recently employed techniques, such as gene-expressing microarrays and proteomics, it is to be expected that new HCC-specific markers will become available in the near future. For all such proposed markers, however, the clinical usefulness has to be carefully evaluated and validated.
KEYWORDS
Tumor markers - α-fetoprotein - lens culinaris agglutinin-reactive AFP - des-gamma carboxyprothrombin
REFERENCES
- 1 Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42 1208-1236
- 2 Bruix J, Sherman M, Llovet J M et al.. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35 421-430
- 3 Srinivas P R, Kramer B S, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol. 2001; 2 698-704
- 4 Srivastava S, Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective. J Nutr. 2002; 132 2471S-2475S
- 5 Pepe M S, Etzioni R, Feng Z et al.. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93 1054-1061
- 6 Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998; 27 273-278
- 7 Sherman M, Peltekian K M, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995; 22 432-438
- 8 Trevisani F, D'Intino P E, Morselli-Labate A M et al.. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001; 34 570-575
- 9 Peng Y C, Chan C S, Chen G H. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology. 1999; 46 3208-3211
- 10 Cedrone A, Covino M, Caturelli E et al.. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology. 2000; 47 1654-1658
- 11 Gambarin-Gelwan M, Wolf D C, Shapiro R et al.. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol. 2000; 95 1535-1538
- 12 Nguyen M H, Garcia R T, Simpson P W et al.. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002; 36 410-417
- 13 Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: a systematic review and critical analysis. Ann Intern Med. 2003; 139 46-50
- 14 Taketa K, Sekiya C, Namiki M et al.. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology. 1990; 99 508-518
- 15 Johnson P J, Poon T C, Hjelm N M et al.. Structures of disease-specific serum alpha-fetoprotein isoforms. Br J Cancer. 2000; 83 1330-1337
- 16 Taketa K, Okada S, Win N et al.. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama. 2002; 56 317-320
- 17 Khien V V, Mao H V, Chinh T T et al.. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers. 2001; 16 105-111
- 18 Yoshida S, Kurokohchi K, Arima K et al.. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol. 2002; 20 305-309
- 19 Wang S S, Lu R H, Lee F Y et al.. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol. 1996; 25 166-171
- 20 Taketa K, Endo Y, Sekiya C et al.. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993; 53 5419-5423
- 21 Oka H, Saito A, Ito K et al.. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol. 2001; 16 1378-1383
- 22 Shiraki K, Takase K, Tameda Y et al.. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology. 1995; 22 802-807
- 23 Sato Y, Nakata K, Kato Y et al.. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993; 328 1802-1806
- 24 Liebman H A, Furie B C, Tong M J et al.. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984; 310 1427-1431
- 25 Liebman H A. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin. Cancer Res. 1989; 49 6493-6497
- 26 Ono M, Ohta H, Ohhira M et al.. Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumour Biol. 1990; 11 319-326
- 27 Aoyagi Y, Oguro M, Yanagi M et al.. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer. 1996; 77 1781-1786
- 28 Mita Y, Aoyagi Y, Yanagi M et al.. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer. 1998; 82 1643-1648
- 29 Nomura F, Ishijima M, Kuwa K et al.. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol. 1999; 94 650-654
- 30 Lamerz R, Runge M, Stieber P et al.. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res. 1999; 19 2489-2493
- 31 Grazi G L, Mazziotti A, Legnani C et al.. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg. 1995; 1 249-255
- 32 Marrero J A, Su G L, Wei W et al.. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003; 37 1114-1121
- 33 Izuno K, Fujiyama S, Yamasaki K et al.. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology. 1995; 42 387-393
- 34 Ikoma J, Kaito M, Ishihara T et al.. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology. 2002; 49 235-238
- 35 Ishii M, Gama H, Chida N et al.. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000; 95 1036-1040
- 36 Shimauchi Y, Tanaka M, Kuromatsu R et al.. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep. 2000; 7 249-256
- 37 Okuda H, Nakanishi T, Takatsu K et al.. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol. 2001; 16 1290-1296
- 38 Hamamura K, Shiratori Y, Shiina S et al.. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer. 2000; 88 1557-1564
- 39 Weitz I C, Liebman H A. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology. 1993; 18 990-997
- 40 Fujiyama S, Tanaka M, Maeda S et al.. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology. 2002; 62(suppl 1) 57-63
- 41 Filmus J, Church J G, Buick R N. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol. 1988; 8 4243-4249
- 42 Bernfield M, Gotte M, Park P W et al.. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999; 68 729-777
- 43 Zhu Z W, Friess H, Wang L et al.. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001; 48 558-564
- 44 Hsu H C, Cheng W, Lai P L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997; 57 5179-5184
- 45 Nakatsura T, Yoshitake Y, Senju S et al.. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003; 306 16-25
- 46 Capurro M, Wanless I R, Sherman M et al.. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125 89-97
- 47 Hippo Y, Watanabe K, Watanabe A et al.. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004; 64 2418-2423
- 48 Kladney R D, Bulla G A, Guo L et al.. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000; 249 53-65
- 49 Marrero J A, Romano P R, Nikolaeva O et al.. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005; 43 1007-1012
- 50 Nakamura T. Structure and function of hepatocyte growth factor. Prog Growth Factor Res. 1991; 3 67-85
- 51 Tomiya T, Tani M, Yamada S et al.. Serum hepatocyte growth factor levels in hepatectomized and nonhepatectomized surgical patients. Gastroenterology. 1992; 103 1621-1624
- 52 Tomiya T, Nagoshi S, Fujiwara K. Significance of serum human hepatocyte growth factor levels in patients with hepatic failure. Hepatology. 1992; 15 1-4
- 53 Shiota G, Okano J, Kawasaki H et al.. Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology. 1995; 21 106-112
- 54 Yanagawa K, Yamashita T, Yada K et al.. The antiproliferative effect of HGF on hepatoma cells involves induction of apoptosis with increase in intracellular polyamine concentration levels. Oncol Rep. 1998; 5 185-190
- 55 Yamagamim H, Moriyama M, Matsumura H et al.. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer. 2002; 95 824-834
- 56 Baserga R. The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res. 1995; 55 249-252
- 57 Baserga R, Hongo A, Rubini M et al.. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997; 1332 F105-F126
- 58 Resnicoff M, Abraham D, Yutanawiboonchai W et al.. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995; 55 2463-2469
- 59 Mazziotti G, Sorvillo F, Morisco F et al.. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer. 2002; 95 2539-2545
- 60 Moon W S, Rhyu K H, Kang M J et al.. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?. Mod Pathol. 2003; 16 552-557
- 61 Poon R T, Ho J W, Tong C S et al.. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004; 91 1354-1360
- 62 Sacco R, Leuci D, Tortorella C et al.. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine. 2000; 12 811-814
- 63 Song B C, Chung Y H, Kim J A et al.. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer. 2002; 94 175-180
- 64 Tangkijvanich P, Tosukhowong P, Bunyongyod P et al.. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 1999; 30 110-114
- 65 Ishizuka H, Nakayama T, Matsuoka S et al.. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med. 1999; 38 927-931
P.D. Dr. H.C. Spangenberg
Department of Medicine II, University Hospital
Hugstetter Strasse 55, D-79106 Freiburg, Germany